Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Hexaconazole
Cat. No.:
OB0225LY-0239
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR and LC-MS.
Size:
Product Overview
Description:
Hexaconazole belongs to the triazole group of compounds, commonly used as fungal inhibitors.
Synonym:
(-)-Hexaconazol; 79983-71-4; 2-(2,4-Dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)hexan-2-ol; PP 523; (RS)-2-(2,4-Dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)hexan-2-ol
CAS No.:
79983-71-4
Compound CID:
66461
Formula:
C14H17Cl2N3O
Formula Weight:
314.21
Specification
Relative Density:
1.29 g/cm3 at 20°C.
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Hexaconazole can be used to inhibit ergosterol biosynthesis.
Library Information
Targets:
Reactive oxygen species
Pathways:
Metabolism; NF-κB; Microbiology/Virology; Immunology/Inflammation
Plate Number:
AOCL-4
Plate Location:
a4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
55 mg/mL; 175.04 mM
